Australia's largest stock trading and investment forum Australia's #1 stock forum

CYP

3.70%

28.0¢ cynata therapeutics limited

Good to see some very good annalise without the personal...

First 552 Last

Share
Profile

Follow
Bazsa

3,861 Posts.

1306

21/06/24

09:27

Post #: 74419003
Share

Originally posted by JB1975: ↑

Yep see your post, still working on next part of reply. I'm rereading a lot of old posts and notes - you did some good summaries (I'd forgotten about shark attacks and ice creams) - I wrote a lot of words - I've re-found a few important quotes from Silviu, Fred Grossman, etc...

Your EAP data from November 2023 and February I don't recall - so it might be something.

I was interpreting SI as having essentially said there was no new data just new analysis of old data as recently as 7 March 2024 (s hare ca fe - hidden gems). But new EAP data (though likely to be confounded) is new data of a sort so I do want to look at it.

I think this is the right stuff (patents MSB are trying to get approved relating to potency assay stuff) to be looking at (to see if they can get a BLA) next time.

To recap old research - 11 patients only from GVHD001 got cells each from a single lot. (Silviu talks about a slide at ODAC to that effect). Only three donors were used. (Geraldine Stornton ODAC). Two of those 11 patients show no or very little reduction in T cell activity measured in blood of patients 28 days apart with the first blood being just before first treatment. (me looking at the graphic).

From such a small amount of data points establishing that the survival at 4 and 5 years was specifically due to the TNFR1 levels and IL2Ralpha levels (and not something else in the donor cells that wasn't measured but might be potent) is an important issue.

MSB can't keep using the same three donors - they'll get old, and can't keep donating bone marrow, and cells already taken from them years ago and banked have limited expansion - so to put reliably potent cells into new patients MSB needs to have a potency matrix that can reliably identify potency factors from cells from new donors. Also from their inventory if they want to use it. The cells from the three donors were from Lonza Walkerville not Lonza Singapore (new plant).

I suppose new EAP data might give data from a wider pool of donors than just the first three if new donor derived lots were used.

To be continued..

Expand

Good to see some very good annalise without the personal attacks.

The error.

"To recap old research - 11 patients only from GVHD001 got cells each from a single lot. (Silviu talks about a slide at ODAC to that effect). Only three donors were used. (Geraldine Stornton ODAC). Two of those 11 patients show no or very little reduction in T cell activity measured in blood of patients 28 days apart with the first blood being just before first treatment. (me looking at the graphic"

This statement is at odds to the chart that summaries the data. 11 lots were used in 001. Two lots showed no change in T cells compared to entry levels.

CYP Price at posting: 24.0¢ Sentiment: Buy Disclosure: Not Held
2 Upvote

1 Great analysis

Reply

Top Stories

Time for retail therapy buying in the shopping Scentre for hot stocks

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

End of FY is a time to juggle wins, losses and capital gains taxes

SS1

Sun Silver submits US$60M Silver Paste Funding Application to US DoE

Eurozone-based companies find new ways to secure a regional lithium supply

There are more pages in this discussion • 32 more messages in this thread...

First 552 Last

Add CYP (ASX) to my watchlist

(20min delay)
Last 28.0¢		Change 0.010(3.70%)		Mkt cap ! $50.29M

Open	High	Low	Value	Volume
26.0¢	28.0¢	26.0¢	$94.42K	352.1K

Buyers (Bids)

No.	Vol.	Price($)
2	29151	26.0¢

Sellers (Offers)

Price($)	Vol.	No.
28.0¢	12092	2

View Market Depth

No.	Vol.	Price($)
2	29151	0.260
1	7359	0.255
1	50000	0.250
1	8000	0.245
3	125942	0.240

Price($)	Vol.	No.
0.280	17629	3
0.290	131206	2
0.295	10160	1
0.305	20000	1
0.310	13257	2

Last trade - 13.40pm 25/06/2024 (20 minute delay)

CYP (ASX) Chart

Good to see some very good annalise without the personal...

Time for retail therapy buying in the shopping Scentre for hot stocks

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

End of FY is a time to juggle wins, losses and capital gains taxes

Sun Silver submits US$60M Silver Paste Funding Application to US DoE

Eurozone-based companies find new ways to secure a regional lithium supply

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Good to see some very good annalise without the personal...

Top Stories

Time for retail therapy buying in the shopping Scentre for hot stocks

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

End of FY is a time to juggle wins, losses and capital gains taxes

Sun Silver submits US$60M Silver Paste Funding Application to US DoE

Eurozone-based companies find new ways to secure a regional lithium supply

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News